Skip to main content
. 2020 Jan 29;99(3):1387–1394. doi: 10.1016/j.psj.2019.11.019

Table 2.

In vitro stability of CIY and IPY to simulated gizzard and intestine conditions as assessed by ELISA.

Treatments Time (h)
0.5 1 2 3
Gizzard
IPY 0.57 ± 0.06a 0.51 ± 0.13a 0.47 ± 0.10b 0.45 ± 0.07a
CIY 0.46 ± 0.10a 1.35 ± 0.7a 1.8 ± 0.36a 0.43 ± 0.05a
P-value 0.87 0.047 0.0002 0.67
Intestine
IPY 0.42 ± 0.09a 0.41 ± 0.07a 0.41 ± 0.11b 0.44 ± 0.11b
CIY 0.45 ± 0.06a 0.50 ± 0.12a 1.36 ± 0.26a 1.13 ± 0.11a
P-value 0.83 0.86 0.0001 0.0001

a-bMeans within a column lacking a common superscripts differ (P < 0.01).

Abbreviations: CIY, capsulated immune yolk; IPY, immune powdered yolk; SGDJ, simulate avian gizzard digestive juice; SIDJ, simulate intestinal digestive juice.

Anti-SI IgY activity remaining over 3 h incubation in SGDJ and SIDJ was measured by ELISA.

Values represent the mean ± SD, (n = 6).